UK markets close in 8 hours 12 minutes

Akebia Therapeutics, Inc. (AKBA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4600-0.0700 (-4.58%)
At close: 04:00PM EDT
1.4500 -0.01 (-0.68%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5300
Open1.5200
Bid1.4500 x 3000
Ask1.4800 x 3000
Day's range1.4200 - 1.5400
52-week range0.5900 - 2.4800
Volume4,105,836
Avg. volume4,781,912
Market cap305.683M
Beta (5Y monthly)0.84
PE ratio (TTM)N/A
EPS (TTM)-0.2800
Earnings date06 May 2024 - 10 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.00
  • PR Newswire

    Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 110,000 shares of Akebia's common stock on March 28, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Benzinga

    FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

    Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia. Vafseo is now approved in 37 countries. The approval of Vafseo is based on e

  • Zacks

    Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD

    Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.